Tada Images -stock.adobe.com
The Waltham, MA-based company is set to acquire Mobidiag Oy, a molecular diagnostics firm, for about $795 million.
It doesn’t look like Hologic will be slowing down with M&A this year. The Waltham, MA-based company has announced its fourth deal – the proposed acquisition of Mobidiag Oy, a molecular diagnostics firm, for about $795 million.
The acquisition is expected to close early in 4Q21.
Mobidiag develops PCR (polymerase chain reaction)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare-associated infections. The Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times ranging from 50 minutes to two hours.